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Objectives. Using data from a multi-institutional data base, we
sought to determine whether hemodynamic data predict duration
of survival in children with primary or secondary pulmonary
hypertension.
Background. Lung transplantation is a therapeutic option for
children with pulmonary hypertension. Appropriate timing of
lung transplantation requires reliable methods of predicting
duration of survival in potential candidates.
Methods. A regional data base was used to obtain cardiac
catheterization data on 50 children with mean pulmonary artery
pressure (mPAP) >25 mm Hg and indexed pulmonary resistance
(Rp) >4.5 Wood units. Data on survival were obtained from the
participating centers.
Results. There were 15 patients without congenital heart dis-
ease (group 1) and 35 patients with congenital heart disease
(group 2) for analysis. Actuarial survival at 1, 2 and 5 years was
86%, 69% and 69% in group 1 and 88%, 88% and 77% in group 2,
respectively (p 5 NS). Hemodynamic variables that predicted
survival on univariate analysis were mean right atrial pressure
(mRAP) (p < 0.0001), mPAP (p 5 0.034), Rp (p < 0.0001) and
pulmonary flow (p 5 0.003), as well as a variable that we
generated—mRAP 3 Rp (p < 0.0001). On multivariate stepwise
logistic regression analysis, mRAP 3 Rp was independently
related to survival. A model using mRAP 3 Rp allows for the
estimation of probability of death at 1 and 2 years after catheter-
ization.
Conclusions. Hemodynamic variables can predict survival in
children with pulmonary hypertension in the presence or absence
of congenital heart defects. This information can be used to
determine the optimal timing of listing for lung transplantation.
(J Am Coll Cardiol 1997;30:554–60)
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Severe pulmonary hypertension may occur in children in
association with congenital heart disease or as an isolated
disease process. Previous reports suggest the prognosis for
such patients is poor, but specific predictors of survival have
not been defined (1–4). Hemodynamic variables including
lower mean right atrial pressure (mRAP), lower mean pulmo-
nary artery pressure (mPAP) and a higher cardiac index have
been shown to predict survival in adults with primary pulmo-
nary hypertension (5). Lower mRAP correlated with survival in
a small group of children with primary pulmonary hyperten-
sion evaluated in Mexico City (6). It is currently unknown
whether hemodynamic variables can predict survival in pedi-
atric patients with irreversible pulmonary hypertension sec-
ondary to congenital heart disease. Lung transplantation is
now a therapeutic option for this condition; however, optimal
utilization of this procedure requires that we reliably estimate
an individual’s chance of survival without transplantation. We
report a retrospective analysis of survival among children with
pulmonary hypertension and elevated pulmonary vascular re-
sistance, with or without congenital heart disease, who under-
went cardiac catheterization. The purpose of this study was to
determine whether hemodynamic variables can be used to
predict survival in such patients.
Methods
Patient selection. Patient histories and catheterization data
were obtained from the Pediatric Cardiac Care Quality Assur-
ance Consortium (PCCC), a data base of cardiac catheteriza-
tion data and surgical procedures on pediatric patients from 28
medical centers (Appendix). The data base, for the period
1982–1992, was searched for four diagnosis codes: fixed pul-
monary vascular disease, pulmonary hypertension, primary
pulmonary hypertension or secondary pulmonary hyperten-
sion. Patients were eligible for the study if they met the
inclusion criteria listed in Table 1. The hemodynamic inclusion
criteria were mPAP .25 mm Hg, indexed pulmonary flow
(Qp) .4.5 Wood units, pulmonary artery wedge pressure
#12 mm Hg if left atrial or left ventricular end-diastolic
pressure had not been obtained and a complete set of hemo-
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dynamic data collected while the patient breathed room air.
The clinical inclusion criteria were age at cardiac catheteriza-
tion .120 days and ,18 years, absence of left heart obstructive
lesions, absence of dilated cardiomyopathy, absence of lesions
with inadequate pulmonary vascular bed (i.e., tetralogy of
Fallot with pulmonary atresia and hypoplastic pulmonary
arteries), absence of surgical intervention after the most recent
cardiac catheterization, absence of lung disease as stated by the
contributing center and at least one point of follow-up avail-
able.
Cardiac catheterization data. Cardiac catheterizations
were performed at 15 different centers, and cardiac catheter-
ization reports were analyzed retrospectively. For the purposes
of this study, a complete and accurate hemodynamic evalua-
tion was defined as follows: 1) arterial pH maintained between
7.30 and 7.50; 2) hemoglobin measured and recorded; 3)
pressure measurements made in the right atrium, main pul-
monary artery, pulmonary capillary wedge (or left atrium),
left ventricle (if pulmonary artery wedge pressure was
.12 mm Hg) and aorta; 4) oxygen saturation measured in the
superior vena cava, right atrium, pulmonary artery, either
pulmonary veins, left atrium or left ventricle and aorta; 5)
cardiac index determined in one of the following ways: the Fick
method, using a value for oxygen consumption that was
measured in a flowthrough hood or that could be estimated
using the patient’s age, heart rate and gender using the tables
of LaFarge and Miettinen (7); or indicator dye or thermodi-
lution in children in whom no intracardiac shunt was demon-
strated by oximetry.
Cardiac anatomic diagnoses were accepted as stated in the
catheterization report; however, if the hemodynamic data were
in conflict with the anatomic diagnosis, the patient was ex-
cluded (on the basis of inadequate catheterization data).
Cardiac catheterization data and registry reports contained
date of birth, date of catheterization and date(s) of surgical
repair, as well as information on systemic diseases and chro-
mosomal abnormalities. For hemodynamic variables in which
cardiac catheterization data are used to calculate values, all
values were recalculated and adjusted if there was a discrep-
ancy. Among patients who had undergone multiple catheter-
izations, data from the single most recent complete catheter-
ization were used to correlate clinical outcome with the most
recent hemodynamic data. Duration of survival was measured
from the time of catheterization to the point of last follow-up
or death. Patients who underwent lung transplantation were
censored on the date of transplantation. Although many
patients had evaluation of their response to pulmonary vaso-
dilators, including oxygen, this sort of testing was not standardized
and thus no attempt has been made to investigate the significance
of reactivity of the pulmonary vascular bed. In patients with
complete atrioventricular canal defects (CAVCD), pulmonary
artery wedge pressures were not obtained. The left atrial pressure
was used in the calculation of their indexed pulmonary arteriolar
resistance (Rp); pulmonary vein stenosis has not been ruled out in
these patients.
Follow-up information. Follow-up information was re-
quested from the participating centers (Appendix). Patients
were identified by a registry identification number, which was
sent to participating centers along with a form asking for the
following information: date of last clinic visit; transplantation
status (i.e., had the patient received a transplant and if so what
type and on what date?); and for patients who had died, date
of death and cause of death. In some cases, this information
was gathered by a representative of the participating center. In
others, one of the investigators (M.L.C.) reviewed clinic charts
and hospital records to complete the follow-up form. Informa-
tion on medications was not obtained.
Statistical methods. Statistical analysis was performed us-
ing STATA 4.0 software (Stata Corporation). Analysis of
demographic and hemodynamic characteristics of patients with
or without congenital heart disease was performed using the
Wilcoxon rank-sum test with the Bonferroni correction. Uni-
variate and multivariate analyses were performed using the
Cox proportional hazards model (8). Duration of survival was
entered as the dependent variable, and the following were
entered as independent variables—age, gender, hemoglobin,
group (i.e., 1 or 2), presence of trisomy 21, mRAP, mPAP,
mean aortic pressure (mAOP), mPAP/mAOP, Qp, indexed
Abbreviations and Acronyms
CAVCD 5 complete atrioventricular canal defect
mAOP 5 mean aortic pressure
mPAP 5 mean pulmonary artery pressure
mRAP 5 mean right atrial pressure
PCCC 5 Pediatric Cardiac Care Quality
Assurance Consortium
Qp 5 indexed pulmonary flow
Qs 5 indexed systemic flow
Rp 5 indexed pulmonary arteriolar
resistance
Rs 5 indexed systemic resistance
VSD 5 ventricular septal defect
Table 1. Inclusion Criteria
Hemodynamic criteria
mPAP .25 mm Hg
Rp .4.5 Wood units
pH .7.30 and ,7.50
Pulmonary artery wedge pressure #12 mm Hg if no left atrial or end-
diastolic pressure measured
Oxygen consumption determined from catheterization data
Complete hemodynamic evaluation with patient breathing room air
Clinical criteria
Age at cardiac catheterization .120 days and ,18 years
Absence of left heart obstructive lesions
Absence of dilated cardiomyopathy
Absence of lesions with inadequate pulmonary vascular bed
Absence of surgical intervention after most recent cardiac catheterization
Absence of lung disease
At least one point of follow-up available
mPAP 5 mean pulmonary artery pressure; Rp 5 indexed pulmonary
arteriolar resistance.
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systemic flow (Qs), Rp, indexed systemic resistance (Rs)
Qp/Qs and Rp/Rs. In addition, we created another variable,
the product of the mRAP and the Rp (mRAP 3 Rp), as a
measure of both the pressure load on the right ventricle and
how well the right ventricle handles that load. Results were
expressed as odds ratios with 95% confidence intervals (CIs).
For continuous variables, the odds ratios were expressed per
unit of measurement. Forward stepwise logistic regression was
used to generate the equation used in the predictive model (9).
The Kaplan-Meier method was used to estimate actuarial
survival. The log-rank test was used to compare survival curves
of two or more groups. The Fisher exact test was used to assess
the significance of frequencies. Throughout the statistical
analysis, p ,0.05 was considered significant, using the Bonfer-
roni correction where appropriate.
Results
Patient group. The search of the PCCC data base yielded
158 patients who initially appeared to meet the inclusion
criteria. At this point, follow-up information was requested
from the participating centers, and the catheterization reports
were further scrutinized. Patients were excluded for the fol-
lowing reasons: pH not reported in the catheterization report
or pH outside the specified range (n 5 46), incomplete
catheterization report (n 5 39), absence of data on room air
(n 5 15), lung disease (n 5 3), age outside the specified range
(n 5 2) and lack of follow-up (n 5 3). Thus, 50 patients were
suitable for further analysis. Patients were classified into two
groups: group 1 consisted of 15 patients without congenital
heart disease. Within group 1, there were four patients who
had other medical problems—one each of the following:
mosaic triploidy, type I hyperlipidemia and primary hyperal-
dosteronism, insulin-dependent diabetes mellitus with seizure
disorder and mental retardation with seizure disorder. Group
2 consisted of 35 patients with congenital heart disease. The
patient profiles are shown in Table 2. The two groups were
comparable with respect to age, hemoglobin, Qs, mRAP,
mPAP, mAOP, Rp, Rs, Qp/Qs, Rp/Rs and gender. They
differed in the incidence of trisomy 21 (43% in group 2 and 0%
in group 1, p 5 0.002) and duration of follow-up (5.1 6 3.6
years in group 2 compared with 2.6 6 2.8 years in group 1, p 5
0.009).
The patients in group 2 had a spectrum of congenital heart
defects: ventricular septal defect (VSD) in eight patients,
CAVCD in six, CAVCD with patent ductus arteriosus in four,
VSD with patent ductus arteriosus in four, VSD with atrial
septal defect in three, atrial septal defect with patent ductus
arteriosus in one, patent ductus arteriosus only in one and
atrial septal defect only in one. In addition, another seven
patients had one each of the following complex lesions: VSD
with patent ductus arteriosus and pulmonary stenosis, “cor-
rected transposition” with VSD, double-inlet left ventricle with
pulmonary stenosis, interrupted aortic arch type A with patent
ductus arteriosus and VSD, truncus arteriosus, transposition of
the great vessels with VSD and transposition of the great
vessels with an intact ventricular septum. Among these patients
with congenital heart disease, 14 (40%) were unrepaired, 5
(14%) were palliated, 9 (26%) had undergone surgical repair
but had residual defects on angiography as reported in the
catheterization summary and 7 (20%) were completely re-
paired. The mean age at complete repair was 4.1 6 3.7 years
(range 1.4 to 12.1). The spectrum of congenital heart defects in
the patients with trisomy 21 was CAVCD in six patients,
CAVCD with patent ductus arteriosus in three, VSD with
patent ductus arteriosus in three, VSD in one and atrial septal
defect with patent ductus arteriosus in one. Of the patients
with trisomy 21, nine (60%) were unrepaired, one (7%) was
palliated, four (26%) had undergone surgical repair but had
residual defects and only one (7%) had been completely
repaired. The low rate of complete repair in the patients with
trisomy 21 compared with those without trisomy 21 was
significant (p 5 0.04). Right to left shunting was present in four
patients (27%) from group 1 and 10 patients (29%) from group
2. No patients in group 2 had systemic disease apart from
trisomy 21.
Survival. Complete follow-up was defined as knowledge of
whether the patient was alive or had survived to lung trans-
plantation. Patients were censored at the time of transplanta-
tion for calculation of actuarial survival. Among patients in
group 1, complete follow-up was available in 93% at 1 year, in
73% at 2 years and in 47% at 3 years. Among patients in group
2, complete follow-up was available in 97% at 1 year, in 94% at
2 years and in 77% at 3 years. Actuarial survival for all patients
is shown in Figure 1 and for each of the two groups in Figure
2. The actuarial survival for group 1 is 86% (95% CI 55% to
96%) at 1 year, 69% (95% CI 35% to 87%) at 2 years and 69%
(95% CI 35% to 87%) at 5 years. The actuarial survival for
group 2 is 88% (95% CI 72% to 95%) at 1 year, 88% (95% CI
72% to 95%) at 2 years and 77% (95% CI 57% to 88%) at 5
Table 2. Patient Profile
Group 1
(n 5 15)
Group 2
(n 5 35) p Value
Age (yr) 8.8 6 4.2 8.1 6 5.3 NS
Hemoglobin (mg/dl) 14.1 6 2.0 15.0 6 2.5 NS
Qp (liters/min per m2) 2.6 6 0.9 3.5 6 1.3 NS
Qs (liters/min per m2) 2.9 6 1.0 3.8 6 2.1 NS
mRAP (mm Hg) 5.5 6 3.5 6.3 6 3.6 NS
mPAP (mm Hg) 59 6 26 63 6 19 NS
mAOP (mm Hg) 78.3 6 12 74 6 10 NS
Rp (Wood units) 23.9 6 16.9 19.0 6 13.3 NS
Rs (Wood units) 28.5 6 13.7 1.3 6 8.0 NS
Qp/Qs 0.93 6 0.15 1.04 6 0.39 NS
Rp/Rs 0.89 6 0.77 1.01 6 0.90 NS
Male 20% 40% NS
Trisomy 21 0% 43% 0.002
Duration of follow-up (yr) 2.6 6 2.8 5.1 6 3.6 0.009
Data are presented as mean value 6 SD or percentage of patients. mAOP 5
mean aortic pressure; mPAP 5 mean pulmonary artery pressure; mRAP 5 mean
right atrial pressure; Qp 5 indexed pulmonary flow; Qs 5 indexed systemic flow;
Rp 5 indexed pulmonary vascular resistance; Rs 5 indexed systemic resistance.
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years. Group 2 was further divided into patients with or
without trisomy 21. Actuarial survival for 1 year, 2 years and 5
years was 93%, 93% and 93% (95% CI 61% to 99%) for those
with trisomy 21 and 85% (95% CI 60% to 95%), 85% (95% CI
60% to 95%) and 79% (95% CI 53% to 92%) for those without
trisomy 21, respectively. The differences in survival are not
significant.
There were four deaths in group 1 (27%) and seven deaths
in group 2 (20%). The causes of death included sudden death
at home in three patients, progressive right heart failure in two,
sudden death in hospital in one, procedure-related in four,
(two after cardiac catheterization, one during lung biopsy and
one after hemothorax during Swan placement to assess re-
sponse to pulmonary vasodilators) and circumstances unknown
in one.
For the purposes of further analysis, the two groups were
combined. The results of the univariate regression analysis are
summarized in Table 3. For continuous variables, the odds
ratios are expressed per unit of measurement, with ranges for
the individual measurements listed. The factors that were
found to be significant predictors of survival were lower mRAP
(p , 0.0001), lower mPAP (p 5 0.034), lower Rp (p , 0.0001),
lower Qp (p 5 0.003) and lower mRAP 3 Rp (p , 0.0001).
Taking into account colinearity, permutations of these vari-
ables were entered into a Cox multivariate analysis. The
variables Qp and PAP did not retain significance. The variable
found to have the best maximal likelihood of fit was mRAP 3
Rp (p , 0.0001). This variable retained significance in the
multivariate regression analysis when group 1 and group 2
were analyzed separately. Figure 3 demonstrates the effect of
mRAP 3 Rp on survival. Patients with mRAP 3 Rp .160 mm
Hg2/liter per min per m2 have a significantly lower predicted
survival than those with a lower mRAP 3 Rp (p , 0.0001).
Patients with a mRAP 3 Rp of 161 to 260 mm Hg2/liter per
Figure 3. Effect of mRAP 3 Rp on actuarial survival. The four curves
represent patients stratified by mRAP 3 Rp ,60, 60 to 160, 161 to 260
and .260 mm Hg2/liter per min per m2. Survival was significantly
better for patients with mRAP 3 Rp #160 mm Hg2/liter per min per
m2 than for those with mRAP 3 Rp .160 mm Hg2/liter per min per
m2 (p , 0.001). Superimposed on this graph, depicted by the open
diamonds, is the actuarial survival for children with cardiovascular
disease after lung transplantation (10). This survival curve falls be-
tween that of patients with mRAP 3 Rp between 161 and
260 mm Hg2/liter per min per m2 and that of patients with mRAP 3 Rp
.260 mm Hg2/liter per min per m2.
Figure 1. Kaplan-Meier survival curve for all 50 patients is depicted by
the open diamonds, and the 95% confidence intervals are depicted by
the solid triangles and solid carats.
Figure 2. Kaplan-Meier survival curves for group 1 (patients without
congenital heart disease) and group 2 (patients with congenital heart
disease). The numbers above the curves represent the number of
patients whose status is known in group 2 at 1, 2 and 3 years. The
numbers below the curves represent the number of patients whose
status is known in group 1 at 1, 2 and 3 years.
Table 3. Univariate Regression Analysis of Variables That Predict Survival
Variable Measured Range
Hazards
Ratio* 95% CI p Value
mRAP 1 to 17 mm Hg 1.36 1.15–1.60 ,0.0001
mPAP 26 to 100 mm Hg 1.03 1.00–1.07 0.034
Rp 4 to 67 Wood units 1.07 1.03–1.10 ,0.0001
Qp 1.2 to 6.4 liters/min per m2 0.35 0.18–0.70 0.003
mRAP 3 Rp 6 to 1,091 mm Hg2/liter
per min per m2
1.01 1.01–1.02 ,0.0001
*Hazard ratios are per unit of measurement. Thus, for a patient with a right
atrial pressure of 16 mm Hg, the instantaneous risk of death is about four times
greater than that for a patient with a right atrial pressure of 4 mm Hg; for a
patient with a product (mRAP 3 Rp) of 200 mm Hg2/liter per min per m2, the
instantaneous risk of death is eight times greater than that for a patient with a
product of 24 mm Hg2/liter per min per m2. Variables tested and not found to be
significant were age, gender, hemoglobin, group (i.e., 1 or 2), presence of trisomy
21, cardiac index, Qp/Qs and Rp/Rs. CI 5 confidence interval; other abbrevia-
tions as in Table 2.
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min per m2 had an estimated 2-year survival rate of 65% (95%
CI 25% to 87%), and those with mRAP 3 Rp .260 mm
Hg2/liter per min per m2 had an estimated 2-year survival rate
of 35% (95% CI 5% to 68%). In Figure 3, superimposed on the
survival curves from patients in this study is the actuarial
survival curve of pediatric patients with cardiovascular disease
undergoing lung transplantation from a previously reported
study (10).
A model was generated using patients with complete
follow-up at 1 and 2 years after catheterization and the variable
mRAP 3 Rp in the logistic regression equation to predict the
probability of death (p):
p 5
ea1b~mRAP3Rp!
1 1 ea1b~mRAP3Rp!
At 1 year, a 5 23.8, b 5 0.010 and p 5 0.0006; at 2 years,
a 5 23.4, b 5 0.011 and p 5 0.0003.
For example, a patient with an mRAP of 5 mm Hg and
Rp of 8 Wood units has a probability of death at 1 year after
catheterization of 3.2%, and at 2 years 4.9%. Similarly, a
patient with an mRAP of 12 mm Hg and Rp of 32 Wood
units has a 58% probability of death at 1 year and 70% at 2
years.
Of the 47 patients with complete follow-up at 1 year, the
model estimated the probability of death at 1 year to be .50%
in four patients, three (75%) of whom were dead at 1 year. Of
43 patients in whom the model predicted the probability of
death at 1 year to be ,50%, 39 (93%) were alive at 1 year. The
model predicted the probability of death to be .50% at 2 years
in four patients, three (50%) of whom were dead at 2 years. In
the 40 patients in whom the model predicted the probability of
death to be ,50% at 2 years, 36 (90%) were alive at 2 years.
Discussion
Predicting survival in children with pulmonary hyperten-
sion. This retrospective analysis represents the largest pub-
lished series of pediatric patients with pulmonary hypertension
in whom complete cardiac catheterization data are available
for analysis, and it demonstrates that hemodynamic variables
(lower mRAP, lower mPAP, lower Qp, lower Rp and lower
mRAP 3 Rp) can estimate predicted survival in these patients.
When multivariate analysis was applied to the data, low
mRAP 3 Rp emerged as a factor independently related to
survival. This variable, generated by multiplying the mRAP
times the Rp, was formulated by us to represent the pressure
load on the right ventricle (Rp) and how well the right ventricle
handles that load (mRAP). Use of this model allows for the
estimation of the probability of death 1 and 2 years after
catheterization. This information could be particularly useful
in the management of children being evaluated for lung
transplantation.
Previous studies of children with pulmonary hypertension
and congenital heart disease have correlated histologic or
angiographic findings with hemodynamic variables (11–14),
but none have examined the relation between hemodynamic
data and survival. Sandoval et al. (6) reported on 18 children
with primary pulmonary hypertension who had undergone
cardiac catheterization. Their patients had a median survival of
4.1 years from the time of diagnosis; lower mRAP and higher
stroke volume index emerged as predictors of survival. Other
investigators have quoted a mean survival of 1 year from the
time of diagnosis among children with primary pulmonary
hypertension (1,15). In a prospective study of adults with
primary pulmonary hypertension through the National Insti-
tutes of Health registry, lower mRAP, lower PAP and a higher
cardiac index correlated with survival (5).
Implications for listing for lung transplantation. Although
medical therapy, including calcium channel blockers (16),
anticoagulation (17) and continuous intravenous infusion of
prostacyclin (18,19), have been shown to prolong survival in
patients with primary pulmonary hypertension, there is no
definitive therapy for this progressive disease. Lung transplan-
tation has become a therapeutic option for children with
pulmonary hypertension, with or without congenital heart
disease, when medical management fails (10,20,21). The opti-
mal time to list patients who choose this therapy is unclear; it
will be influenced by predicted survival without lung transplan-
tation, the waiting time for donor organs and the predicted
survival after lung transplantation. Information on waiting
times for donor organs and actuarial survival after lung
transplantation is available from the International Society for
Heart and Lung Transplantation (22). That information, com-
bined with hemodynamic data, can be used to make rational
decisions regarding the timing of listing patients for lung
transplantation.
Figure 3 shows the actuarial survival among the study patients,
stratified by the product variable mRAP 3 Rp. Superimposed on
these survival curves is the actuarial survival among children with
cardiovascular disease undergoing lung transplantation (10). Pa-
tients with a mRAP 3 Rp ,160 mm Hg2/liter per min per m2
would be expected to survive longer without lung transplantation
than with lung transplantation, and thus this intervention would
be unwarranted. Patients with a mRAP between 161 and
260 mm Hg have survival comparable to children undergoing lung
transplantation; those with a mRAp 3 Rp .260 mm Hg2/liter per
min per m2 have a worse survival than those undergoing lung
transplantation. Current experience indicates that patients who
survive the perioperative period of lung transplantation have
better exercise capacity and subjectively improved quality of life
than the pretransplant patients with severe pulmonary hyperten-
sion (10,23). Thus, a reasonable strategy would be to list a patient
for lung transplantation when the mRAP 3 Rp exceeds 160 mm
Hg2/liter per min per m2.
The rate of disease progression among children with pul-
monary hypertension remains unknown. Until recently, cardiac
catheterization has been used to confirm the diagnosis of
irreversible pulmonary hypertension, with subsequent cardiac
catheterization studies considered to carry substantial risk with
little benefit (24). However, as hemodynamic variables ob-
tained with cardiac catheterization can help predict survival
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probability, the current availability of lung transplantation for
previously untreatable disease(s) implies that serial cardiac
catheterizations should play a role in managing these patients.
Primary versus secondary pulmonary hypertension. Al-
though it is generally recognized that patients with primary
pulmonary hypertension have a shorter life expectancy than
those with pulmonary hypertension in association with congen-
ital heart disease, our analysis did not reveal a survival
difference based on diagnosis. Survival in our study was
measured from the time of cardiac catheterization, not from
the time of disease onset; the latter is unknowable in this group
of patients. Our findings indicate that elevated RAP and Rp
predict a shorter duration of survival, regardless of the diag-
nosis. It may very well be the case that it takes longer to reach
a given RAP and Rp when the underlying disease is congenital
heart disease rather than primary pulmonary hypertension.
Our study does not and cannot address this question.
Study limitations. A retrospective study using patients
from a registry has inherent shortcomings. The use of precisely
defined inclusion criteria, particularly with respect to cardiac
catheterization data, selected a specific target patient group
but also reduced the number of patients available for study.
We did not detect a difference in the variables that predict
survival in group 1 versus group 2; the number of patients in
this study may have been too small to detect differences.
However, in subgroup analysis, all the stated predictors re-
tained their significance. There are a number of important
characteristics that we were unable to study. These include the
predictive value of New York Heart Association functional
class, the effects of medical treatment on survival and the
predictive value of response to vasodilators. Because they have
been shown to increase survival, calcium channel blockers and
prostacyclin are used with increasing frequency; thus, a study
of the “natural history” of pulmonary hypertension (i.e., with-
out vasodilator therapy) is not possible. For this reason, the
largest and most complete available study of survival in
patients with primary pulmonary hypertension was carried out
in a patient group that was heterogeneous with regard to
medical management (5), and we have had to do the same.
Whether the predictive value of hemodynamic variables is
changed by such therapy is unknown.
Conclusions. In children with pulmonary hypertension, in
the presence or absence of congenital heart disease, hemody-
namic variables can estimate survival probability. This infor-
mation may be helpful to physicians caring for children with
severe pulmonary hypertension in whom lung transplantation
is being considered. Serial cardiac catheterizations in regional
centers specializing in the evaluation of these high risk patients
may now yield specific information with which to estimate
survival and may serve to define the rate of disease progres-
sion. Further studies that address functional status and re-
sponse to pulmonary vasodilators are needed. Prospective
application of this model to children with pulmonary hyper-
tension will be necessary to validate this preliminary study.
Appendix
Centers Participating in the Pediatric Cardiac Care
Quality Assurance Consortium That Contributed
Data for This Study
All Children’s Hospital, St. Petersburg, Florida; Arkansas Children’s Hospital,
Little Rock, Arkansas; Cardinal Glennon Hospital, St. Louis, Missouri; Children’s
Health Care–Minneapolis, Minneapolis, Minnesota; Children’s Health Care–St.
Paul, St. Paul, Minnesota; Children’s Medical Center of Dallas, Dallas, Texas;
Children’s Mercy Hospital, Kansas City, Missouri; Columbus Children’s Hospital,
Columbus, Ohio; Children’s National Medical Center, Washington, DC; Fargo
Clinic, Fargo, North Dakota; LeBonheur Children’s Medical Center, Memphis,
Tennessee; Mayo Clinic, Rochester, Minnesota; Mercy Hospital Medical Center,
Des Moines, Iowa; Oschner Foundation Hospital, New Orleans, Louisiana; St.
Louis Children’s Hospital, St. Louis, Missouri; St. Luke’s Regional Medical Center,
Boise, Idaho; University of Arizona Health Sciences Center, Tucson, Arizona;
University of Iowa Hospitals and Clinic, Iowa City, Iowa; University of Kentucky
Medical Center, Lexington, Kentucky; University of Miami School of Medicine,
Miami, Florida; University of Minnesota Hospital, Minneapolis, Minnesota;
University of Mississippi Medical Center, Jackson, Mississippi; University of Ne-
braska Medical Center, Omaha, Nebraska; and West Virginia University, Morgan-
town, West Virginia.
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